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Abstract
The relevant efﬁcacy of monoclonal antibodies (mAbs) has resulted in the successful treatment of several diseases, although susceptibil-
ity to infections remains a major problem. This review summarizes aspects of the literature regarding viral infections and mAbs, speciﬁ-
cally addressing the risk of infection/reactivation, the measures that can reduce this risk, and the role played by the laboratory of
clinical virology in monitoring patients undergoing mAb therapy.
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Introduction
The treatment of several medical conditions, such as cancer
and autoimmune diseases, has been revolutionized following
the introduction of biological therapies targeting speciﬁc
components of pathways involved in the pathogenic mecha-
nisms. These agents are mainly monoclonal antibodies
(mAbs). Immunotherapy developed with the discovery of
antibody structure and the introduction of hybridoma tech-
nology, which provided the ﬁrst source of mAbs [1]. Initially,
murine mAbs (sufﬁx -omab) suffered from major problems
resulting from immune complex formation and inadequate
recruitment of host effector functions. To overcome this,
murine molecules were engineered to remove immunogenic
content and to increase the immunomodulant efﬁciency; this
was achieved by the production of chimeric (composed of
murine variable regions fused onto human constant regions,
c. 65% human component; sufﬁx -ximab) and humanized (pro-
duced by grafting murine hypervariable amino acid domains
into human antibodies, c. 95% human component; sufﬁx -zu-
mab) antibodies. Extensive research is currently being con-
ducted to produce mAbs for several diseases, such as
rheumatoid arthritis, multiple sclerosis, inﬂammatory bowel
diseases, and many types of neoplasm. However, susceptibility
to infections remains a major concern, as the targets of
these mAbs are molecules or cells involved in immune
anti-infectious pathways. The severity of these infections can
be inﬂuenced by the protocol utilized (dosage, frequency,
and route of administration). Considering the most used
mAbs in clinical practice, the reported infectious complica-
tions remain low in frequency, and are limited mainly to
mAbs targeting antigens such as CD52, CD20, tumour
necrosis factor (TNF)-a, and the integrin very late antigen
(VLA)-4 [2]. Besides bacterial and fungal infections, viral
infections/reactivations are important factors limiting the uti-
lization of biological agents (Table 1).
Anti-CD52: Alemtuzumab
Alemtuzumab is a humanized anti-CD52 antibody (Campath)
that is mainly expressed on the surface of peripheral B-cells
and T-cells, both normal and malignant, monocytes, thymo-
cytes, natural killer cells, and macrophages; it is not expressed
on erythrocytes or platelets. This mechanism of action makes
alemtuzumab indicated for the treatment of chronic lympho-
cytic leukaemia, non-Hodgkin lymphomas, post-transplantation
patients, and graft-versus-host disease. Treatment results in
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lymphoid ablation. In this context, reactivation of cytomegalo-
virus (CMV) is an important problem, having been reported in
6–66% of patients [3]. The wide range of reported incidence
might be a result of differences in study design, population, and
viral detection modes; moreover, earlier studies might have
under-reported the incidence of CMV reactivation, because
CMV was not routinely monitored. Nevertheless, the beneﬁt/
risk ratio favours its utilization with close virological monitor-
ing for early detection of reactivation, as pre-emptive treat-
ment prevents the occurrence of potentially life-threatening
disease, and the initiation of anti-CMV treatment avoids the
interruption of alemtuzumab. CMV reactivation is typically
observed between 4 and 6 weeks after the initiation of treat-
ment [4]. Usually, given the high background of CMV seroposi-
tivity, reactivation is monitored weekly with a sensitive
detection method (CMV-DNAemia). In clinical trials, among
the exclusion criteria for recruitment, CMV-DNAemia positiv-
ity at screening makes the patient not eligible. Treatment to
reduce the viral load to a non-detectable level is required, and
study entry is possible once the infection has been treated.
Among exclusion criteria are active or prior viral hepatitis B
or C or positivity for hepatitis B serology. Patients with hepati-
tis B surface antibodies (HBsAbs) with a documented history
of prior hepatitis B immunization are eligible if other criteria
are met (i.e. negativity for hepatitis B surface antigen (HBsAg),
hepatitis B core antibody, and anti-hepatitis C virus (HCV)
antibody). Patients with human immunodeﬁciency virus (HIV)
infection are excluded. In Fig. 1, an algorithm for the evalua-
tion of viral infections in relation to the administration of ale-
mtuzumab is given.
Anti-CD20: rituximab
Rituximab (Mabthera or Rituxan) is a chimeric mAb targeting
the CD20 molecule, and is expressed on the normal B-cell
lineage (from pre-B stage to memory stage) as well as on
abnormal B-lymphocytes. Rituximab has been approved for
the treatment of indolent CD20, B-cell non-Hodgkin lympho-
mas, chronic lymphocytic leukaemia, and moderate-to-severe
rheumatoid arthritis. Several viral infections related to ritux-
imab have been reported. In a meta-analysis [5], 64 cases of
serious viral infection after rituximab treatment were found,
in particular hepatitis B virus (HBV) reactivation in patients
with chronic lymphocytic leukaemia and lymphomas [5–9];
CMV infection, varicella-zoster virus infection and other
infections were also found. Close monitoring for viral infec-
TABLE 1. Main viral infections/reactivations in patients undergoing monoclonal antibody therapy and monitoring or recom-
mendations
Anti-CD52 (alentuzumab) Anti-CD20 (rituximab)
TNF-a antagonists (inﬂiximab,
etanercept, adalimumab,
certolizumab pegol)
Anti-integrin
VLA-4 (natalizumab)
CMV 6–66% reactivation within 4–6 weeks,
close monitoring [3,4]
Few cases, close monitoring [5] Poorly known [22–26]
HBV Active and prior infection as exclusion
criteria in clinical trials
20–55%, close monitoring [5–10] Case reports, close monitoring, exclusion
criteria in clinical trials, but consider
occult infection [18–21]
HCV Active and prior infection as exclusion
criteria in clinical trials
Poorly known, close monitoring [14,15]
VZV Few cases [5] Poorly known [28]
JCV 57 cases [11,12] 30 cases [12]
EBV Up to 40% reactivation, <1% risk of
PTLD [33]
Poorly known [27]
HPV Poorly known [29]
CMV, cytomegalovirus; EBV, Epstein–Barr virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papillomavirus; JCV, JC virus; PTLD, post-transplantation lympho-
proliferative disorder; TNF, tumour necrosis factor; VLA, very late antigen; VZV, varicella-zoster virus.
Test CMV DNA
before treatment
with alemtuzumab
Negative
Start alemtuzumab
and monitor CMV
DNA weekly
Positive
Antiviral treatment
to reduce viral load
to a non-detectable
level, then start
alemtuzumab
Active or prior viral
hepatitis B or C or
positive serological
markers for HBV
No treatment with
alemtuzumab
HBsAb-positive
Negative for HBsAg,
HBcAb, anti-HCV
Treatment with
alemtuzumab
Positive for HbsAg,
HBcAb or anti-HCV
No treatment
with alemtuzumb
FIG. 1. Algorithm for the evaluation of viral infections in relation to
the administration of alemtuzumab. CMV, cytomegalovirus; HBcAb,
hepatitis B core antibody; HBsAb, hepatitis B surface antibody;
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hep-
atitis C virus.
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tions, particularly HBV and CMV, by molecular methods is
recommended. Periodic monitoring of HBV DNA may pre-
dict HBV reactivation, and is thus advantageous in terms of
cost; it is also essential in cases with HBV DNA mutations
and when antibody expression is weak. The identiﬁcation of
HBV reactivation at an early stage is important; therefore, in
addition to HBV DNA monitoring, evaluation of changes in
anti-HBV titres is recommended [10]. Viral reactivation of
the polyomavirus JC virus (JCV) from sites of latency leading
to the development of infection and destruction of the oligo-
dendrocytes is the pathogenic mechanism responsible for
progressive multifocal leukoencephalopathy (PML). To date,
57 PML cases have occurred in patients treated with ritux-
imab [11,12]. A high degree of awareness for PML facilitates
case identiﬁcation; as a deﬁnitive diagnosis of PML is based
on clinical, neuroimaging and histopathological ﬁndings, as
well as on the detection of JCV in the brain tissue, less inva-
sive methods based on the detection of JCV DNA in cere-
brospinal ﬂuid have been proposed. Evaluation of JCV DNA
on serum specimens seems to have low operating character-
istics, given the rarity of PML and the high incidence of tran-
sient viraemia (up to 18% in HIV patients without PML) [13].
TNF-a antagonists
Monoclonal antibodies that antagonize TNF-a (i.e. inﬂiximab,
etanercept, adalimumab, and certolizumab pegol) are used for
several inﬂammatory diseases, such as Crohn’s disease, rheu-
matoid polyarthritis, psoriasis, ankylosing spondylitis, and juve-
nile idiopathic arthritis. Whereas the association with an
increased risk of severe bacterial infection and reactivation of
tuberculosis has been recognized, the impact on viral infec-
tions is less well known. There is little information on long-
term safety and efﬁcacy in patients with chronic HBV or HCV
and/or HIV infection. However, history or current active HBV,
history of HCV, and HIV infection are exclusion criteria for en-
rolment in clinical trials. As regards HCV, elevated levels of
TNF-a are associated with chronic infection, and there is
growing evidence that the pathogenesis of hepatocyte destruc-
tion may be mediated by the upregulation of inﬂammatory
cytokines such as TNF-a. Therefore, TNF-a antagonists may
be beneﬁcial when used in cases of HCV [14,15], and there are
some reports indicating that anti-TNF-a therapy in the setting
of HCV appears to be safe. However, as the role of TNF-a is
complex, the Food and Drug Administration has pointed out
the possible risk of reactivation of chronic viral hepatitis.
Overall, data on safety and efﬁcacy are conﬂicting; therefore,
the presence of HCV should not be an absolute contraindica-
tion, given appropriate pretreatment screening and close mon-
itoring. For selected patients, anti-TNF-a therapy in the setting
of HCV appears to be safe, without an apparent inﬂuence on
the underlying infection. Interval monitoring of serum amin-
otransferases and HCV viral load is recommended. Elevated
levels of TNF-a are also seen in patients with chronic HBV
infection, and, in these patients, it may play a role in clearing
and controlling replication by synergizing with interferon; inhi-
bition of TNF-a could theoretically lead to enhanced viral rep-
lication [16,17]. Reports of patients with chronic HBV
infection who were treated with inﬂiximab or etanercept, and
developed severe reactivation, sometimes with fulminant hep-
atitis, have been published [18–21]. In most cases, patients had
chronic HBV infection with HBsAg positivity, but in others ful-
minant hepatitis was associated with a previously unrecognized
HBsAg-carrier condition. For HBsAg-negative patients with a
known history of HBV infection, the risk of reactivation is very
low, but it cannot be totally excluded. Patients who are persis-
tently HBsAg-negative but have an occult HBV infection have
also been described. These patients may be at risk of develop-
ing a ﬂare of hepatitis during the course of anti-TNF-a treat-
ment, as this may interrupt the suppression of viral replication
and gene expression that is typical for the occult HBV infection
[17]. Evaluation of the risk/beneﬁt proﬁle for speciﬁc antiviral
treatment with lamivudine should be performed [17]. In con-
clusion, screening for HBV in all patients prior to treatment
with anti-TNF-a agents is recommended and, if treatment has
been initiated, carriers of HBV should be closely monitored
for laboratory and clinical signs of viral reactivation during
therapy and for several months following its termination.
Few data on the risk of reactivation of herpesvirus infec-
tions are available. Several cases of CMV infection have been
reported, although severe clinical manifestations are rare.
Authors have suggested the assessment of CMV pp65-anti-
gen levels or quantiﬁcation of CMV DNA in symptomatic
patients [22–26]. Limited information is available on Epstein–
Barr virus reactivation and JCV. Large studies with long fol-
low-up are needed to deﬁne the risk and opportunity for
viral monitoring. Epstein–Barr virus is associated with
lymphoproliferative diseases in immunosuppressed patients,
and inﬂiximab treatment has resulted in transient elevations
in viral load in some patients, although at levels lower than
those associated with lymphoproliferative disorders [27].
Similarly, limited data are available on varicella-zoster virus,
and screening recommendations for the presence of antibod-
ies prior to treatment or prophylactic vaccination in non-
immune patients remain questionable [28].
Speciﬁc effects of anti-TNF-a therapy on human papilloma-
virus-associated diseases remain unknown, with very few
reports suggesting a signiﬁcantly increased risk in patients with
inﬂammatory bowel diseases treated with inﬂiximab [29].
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HIV is considered to be one of the relative contraindica-
tions for anti-TNF-a therapy; however, its safety in HIV-
infected patients is unknown. Its use should be reserved for
highly selected patients, although further studies are needed.
The potential impact of the loss of HIV control needs to be
determined before a clear recommendation; to promptly
identify reactivation of HIV can be established; close moni-
toring of clinical and laboratory parameters in these patients
is mandatory [17,30].
Overall, although several guidelines regarding viral infec-
tion monitoring in immunocompromised patients are avail-
able, few address biological therapy. The appropriate
serological tests are poorly deﬁned, although evaluation of
HBV status is widely supported, and HCV and HIV testing
seems to be justiﬁed in high-risk patients. The European
Crohn’s and Colitis Organisation consensus statement rec-
ommends universal testing (HBsAg, anti-HBs, anti-HBc) and
HBV vaccination in all patients with inﬂammatory bowel dis-
ease, whereas no recommendations have been deﬁned for
HCV [31]. On the contrary, a consensus statement on pre-
treatment testing in rheumatology patients recommends
screening for HBV and HCV in all patients, without a deﬁned
serological strategy [32].
Anti-VLA-4
Natalizumab (Tysabri) is a selective adhesion molecule inhibi-
tor, the target of which is the a4-subunit of the VLA-4
receptor. Natalizumab binds to a4-integrin expressed on the
surface of activated T-cells and other mononuclear leuko-
cytes, where it prevents adhesion between the endothelial
cell and the immune cell. This action inhibits the migration of
leukocytes into the central nervous system. The main indica-
tion for natalizumab treatment is relapsing-remittent highly
inﬂammatory multiple sclerosis. However, the same mecha-
nism of action implies decreased local immune surveillance,
and thus a possible contribution to an increased risk of PML,
a demyelinating disease caused by lytic replication of JCV in
oligodendrocytes that is observed in the setting of profound
cellular immunosuppression, such as in HIV patients and indi-
viduals exposed to potent antilymphocyte drugs, such as
natalizumab, and other mAbs, such as rituximab and
efalizumab.
More than 30 PML cases have been reported worldwide
in patients receiving natalizumab monotherapy for multiple
sclerosis, and the data suggest that PML incidence increases
with the number of infusions (increased risk after 2 years of
therapy). Currently, c. 30 000 patients treated or on treat-
ment with natalizumab are being monitored for PML [12].
Conclusions
The elevated efﬁcacy of mAbs is counterbalanced by an
increased risk of infectious complications. The complete spec-
trum of viral diseases complicating their administration is still
poorly known, although data are accumulating. Similarly, the
virological screening and monitoring that should be performed
in these patients are still undeﬁned and vary greatly, depending
on underlying disease, type of patient, and protocol. Particular
attention is required for the monitoring of herpesviruses, JCV,
HBV, and HCV, and the data that are being obtained could
form the basis for deﬁning consensus guidelines that take into
account the evaluation of viral status pretreatment, and viral
replication/reactivation during therapy and following its inter-
ruption. The possible role played by the speciﬁc cellular
immune response in containing viral replication remains to be
determined, and it is likely that viro-immunological monitoring
could contribute to a better understanding of the immunogical
background underlying the occurrence of viral complications
and to improving their clinical management. Overall, the role
played by the virology laboratory is relevant, as the basal eval-
uation of viral infection and subsequent monitoring in patients
treated with biological agents could allow successful therapy
to be started or continued in cases for which there are few
treatment options. As the beneﬁts of these agents outweigh
their risks, the formulation of speciﬁc recommendations could
allow the identiﬁcation of a small group of patients in whom
the treatment cannot be used or must be interrupted. The
development of speciﬁc recommendations and guidelines is
becoming all the most important with the increasing utilization
of these agents in different clinical contexts.
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